RainDance Technologies Appoints John A. Luckey VP of Product Development
Complete the form below to unlock access to ALL audio articles.
RainDance Technologies, Inc. has announced the appointment of John Luckey, Ph.D., as its new Vice President of Product Development.
Dr. Luckey brings more than 20 years of experience leading teams tasked with developing biotechnology systems and technology platforms. During his career, he has held senior product and platform development positions in companies including Roche NimbleGen, where he directed research and development activities for improving and expanding the company’s core DNA microarray synthesis technology and related instrumentation.
At Roche, he also liaised with 454 Life Sciences development teams and participated on the global team tasked with defining a strategy for applying NGS technology to high-value clinical diagnostics applications. Dr. Luckey also managed product development and engineering activities at MJ Research, contributing to the design and development of the Opticon product family and Opticon Monitor software.
In 1994, he founded GeneSys Technologies and brought to market the BaseStation DNA Fragment Analyzer, an ultrathin gel electrophoresis system that he had designed, developed and patented. Dr. Luckey holds a Ph.D. in Analytical Chemistry and an M.B.A. in Executive Management from the University of Wisconsin, Madison.
“RainDance has developed a unique and powerful core droplet technology that has the potential to transform the industry because of its unmatched ability to provide accurate, early detection and detailed quantitative analysis of rare genetic abnormalities from complex samples,” said Dr. Luckey. “I am honored to join a talented team dedicated to making a profound difference in the understanding of the genetic basis of disease states.”
“John’s appointment further demonstrates RainDance’s commitment to recruiting and building a team passionate about developing and commercializing a new generation of genomic technologies. We are focused every day on delivering the products our customers and partners need to succeed in disease research,” said Roopom Banerjee, President and CEO of RainDance Technologies.”
Complex Genetics Made Simple
RainDance Technologies offers an innovative product portfolio to research cell-free and cell-based biomarkers for hereditary risk predisposition, initial detection, pathology, and residual disease. The company’s products include:
• RainDrop® Digital PCR System: Ultra-sensitive digital PCR system for research of early detection and monitoring of biomarkers for cancers, viruses, pathogens, and immune disorders.
• ThunderBolts™ Cancer Panel: Next-Generation Sequencing (NGS) panel enabling highly sensitive, rapid, low input, and primary tumor profiling research in fresh biopsy, plasma and FFPE samples.
• ThunderStorm® NGS Content Enrichment System: High-throughput, fully automated NGS content enrichment solution enabling researchers to generate what we believe to be the best-in-class data on large-scale disease panels, while delivering affordable workflow for high-volume studies.
